Emergent BioSolutions (EBS) Other Non-Current Assets (2010 - 2026)

Emergent BioSolutions' Other Non-Current Assets history runs 16 years deep, the most recent figure standing at $13.0 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 251.35% year-over-year to $13.0 million in Q1 2026; TTM through Mar 2026 was $13.0 million, a 251.35% increase from a year earlier, with the FY2025 full-year figure at $14.2 million, up 132.79% from the prior year.
• Other Non-Current Assets slipped to $13.0 million in Q1 2026 per EBS's latest filing, from $14.2 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $57.1 million in Q1 2022 and bottomed at $500000.0 in Q1 2024.
• The 4-year median for Other Non-Current Assets is $9.0 million (2024), against an average of $17.5 million.
• Across the five-year window, Other Non-Current Assets sank 60.08% in 2022 and surged 640.0% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $40.8 million in 2022, then plunged by 85.05% to $6.1 million in 2024, then surged by 132.79% to $14.2 million in 2025, then declined by 8.45% to $13.0 million in 2026.
• Per Business Quant, the three latest EBS Other Non-Current Assets figures stand at $13.0 million (Q1 2026), $14.2 million (Q4 2025), and $11.6 million (Q3 2025).